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The World of Placebos
BY ZACHARY WANG ’20

Introduction
The Placebo Effect is a fascinating but
poorly understood mystery of medicine and
human biology. Its workings continue to
surprise scientists and patients everywhere.
This is a brief introduction to the placebo effect
from its early roots to current issues and new
discoveries in the field.

Then...
The First “Placebo”
In the 16th century, religious authorities
conceived of a unique way to test whether or
not someone was actually possessed (Lemoine,
2015). When individuals showed questionable
signs of diabolical possession, they would be
given false relics. If the “possessed” acted as
if they were real, the healer would be able to
deduce that the seizures or other symptoms
were either fake, or the result of an overactive
imagination. In this manner, one of the earliest
documented instances of using an ineffectual
replica of a real treatment was conceived.

The First “Actual” Placebo
In 1752, James Lind, a doctor in the Royal
Navy, published “A Treatise of the Scurvy” in
which he unknowingly performed the first
recorded use of placebo groups (Lemoine, 2015).
The inventor of what would one day be called
a “controlled trial,” Lind selected 12 sailors
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suffering from scurvy and divided them into
groups of two, assigning each group one of six
different treatments. The groups received either
cider, an elixir of vitriol (sulfuric acid), vinegar,
seawater, lemons and oranges, and, lastly, a
mixture of garlic, mustard, and horseradish
root, respectively. The sailors in the lemons and
oranges group healed in days as well as those
in the cider group, though not as quickly. The
other four groups were the placebo groups, and
their treatment proved to be fatal. Ethically,
one would hope that Dr. Lind did not intend to
kill the other four groups, given the substances
administered were considered therapeutic at the
time, though not for the treatment of scurvy.

Figure 1: Drugs earlier
approved by the FDA (such as
Prozac) are now failing further
tests due to the placebo effect.
Source: Wikimedia Commons
(Credit: Tom Varco)

Medicine Embraces the Placebo
It took until 1785 for the term “placebo”
to first show up in the Motherby’s New
Medical Dictionary, where it is defined as “a
commonplace medication or method” (Lemoine,
2015). The word “commonplace” should
probably be taken to mean “overused and
unimportant.” The first time the word appeared
in its modern form was 1958, after the advent of
double-blind controlled trials with randomized
assignment. From this point on, placebos gained
scientific respectability in contrast to the earlier
connotation of pseudoscience.

The Discovery of the Placebo Effect
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Figure 2: Pharmaceutical
companies like Merck are
facing the consequences of
the increasingly powerful
placebo effect, as well as their
customers.
Source: Wikimedia Commons
(Credit: Merck KgaA)

“Pain that was least
natural in origin,
i.e. experimental
pain triggered in
a laboratory on
healthy subjects,
was least responsive
to placebos whereas
natural pain, like
chest pain, was
most sensitive to
placebos.”
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In a famous article published in the Journal
of the American Medical Association in 1955,
using data from 15 studies encompassing 1082
patients with varied types and degrees of
pain, Henry K. Beecher showed that a placebo
analgesic is effective, on average, in 35.2% of
cases, though individual studies ranged from 4%
to 86% efficacy (Beecher, 2015). Pain that was
least natural in origin, i.e. experimental pain
triggered in a laboratory on healthy subjects,
was least responsive to placebos whereas
natural pain, like chest pain, was most sensitive
to placebos. Since then, countless publications
have quantified the effectiveness of placebos
and the existence and importance of the
placebo effect, varying with the patient’s and
physician’s awareness of the placebo. Thus, the
placebo effect gained fame as an impressive feat
of human biology and legitimacy in the eyes of
the medical community.

...and Now
The Ailing Pharmaceutical Industry
The Problem:
Merck was in trouble. In 2002, the
pharmaceutical giant was rapidly falling behind
its competitors in sales (Silberman, 2009). To
make matters worse, patents on five best-selling
drugs were about to expire, allowing cheaper
generics to flood the market. The company had
not introduced a truly new product in three
years, and its stock was plummeting. In an
interview, Edward Scolnick, Merck’s research
director at the time, described his plan to bring
Merck back to the top. Fundamental to this
strategy was a new focus on antidepressants, a
field where Merck had previously lagged behind
its competitors who were making some of the
most profitable drugs such as Zoloft, Prozac,
and Xanax in the world (Grohol, 2016). This
plan hinged on an experimental antidepressant
codenamed MK-869. And though still in clinical
trials, it was shaping up to be a blessing to Merck
and its leadership. The drug exploited human
brain chemistry in brilliant and innovative ways
with little to no side effects. It tested brilliantly

early on, and Merck representatives showed
off its amazing potential at a meeting of 300
securities analysts (Silberman, 2009).
Though doing well on the surface, MK-869
was starting to falter (Drugs in R & D, 2002).
Although many test subjects felt that the drug
lifted their sense of hopelessness and anxiety,
nearly the same number of subjects did so as
well with a placebo. Thus, Merck’s foray into
antidepressants failed. In further testing, MK869 proved to be no more effective than placebos.
Merck’s MK-869 wasn’t the only highly
anticipated medical breakthrough undone by
the placebo effect (McGoey, 2010). From 2001
to 2006, the percentage of new products pulled
from development after Phase II trials, where
they are first tested against placebos, shot up
20%. Failure in the more extensive Phase III trials
rose by 11%. So despite unprecedented amounts
of investment in research and development,
the FDA only approved 19 original remedies
in 2007—the fewest since 1983—and 24 in 2008.
Half of all medications that fail in late-stage
trials are undone due to their inability to beat
out a simple sugar pill.

The Consequences:
What’s the fallout of this phenomenon?
Fewer new medicines are becoming available
to suffering patients and further financial
woes troubling the pharmaceutical industry
(Silberman, 2009). In November of 2009, a new
type of gene therapy for Parkinson’s disease,
championed by the Michael J. Fox Foundation,
was abruptly withdrawn from Phase II trials
after unexpectedly tanking against placebo. A
stem-cell startup called Osiris Therapeutics got
a drubbing on Wall Street that March, when it
suspended trials of its pill for Crohn’s disease,
an intestinal ailment, citing an “unusually high”
response to placebo. Two days later, Eli Lilly
broke off testing of a much-touted new drug for
schizophrenia when volunteers showed double
the expected level of placebo response.
And it’s not just new drugs that are failing
against placebos. Products that have been
available for decades, like Prozac, are now failing
in more recent follow-up testing (McGoey,
2010). If these same drugs were being developed
now, they may not pass FDA approval.
According to drug developers, it’s not that
the old medications are getting weaker, but that
the placebo effect, a beneficial effect produced
by an inert placebo drug or treatment, is getting
stronger (Spiegel, 2010). And it appears that the
placebo effect is not just becoming stronger, but
also increasing in breadth.

Effectiveness of Open Label Placebos
Linda Buonanno had suffered 15 years of
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intense cramps, bloating, diarrhea and pain she
describes as “worse than labor” (Fleming, 2017).
She was willing to try anything to get relief
from her irritable bowel syndrome (IBS) and
leapt at the chance to take part in a trial of an
experimental new therapy. Her hope turned to
disappointment, however, when the researcher
handed her a bottle of capsules he described
as placebos containing no active ingredients.
Nonetheless, she took the pills twice daily.
Four days later, her symptoms all but vanished.
“I know it sounds crazy,” says Buonanno, of
Methuen, Massachusetts. “I felt fantastic. I knew
they were just sugar pills, but I was able to go
out dancing and see my friends again.” Placebos
have a reputation problem. It is widely believed
they are only effective when those taking them
are deceived into thinking they are taking real
drugs. However, prescribing dummy or fake
treatments is unethical. Yet in Buonanno’s case
there was no deception and she experienced
substantial relief. And she is not alone.
On the 27th of April 2017, clinical
epidemiologist Dr. Jeremy Howick and a group
of other scientists working out of the University
of Oxford, Harvard Medical School, and multiple
psychology departments published the Effects
of placebos without deception compared with no
treatment (Charlesworth, 2017). A meta-analysis
and review of five research studies covering 260
patients, showing the effectiveness of “openlabel” placebos for a number of health issues.
“Open-label” placebos are normal placebos,
except that patients know that they’re placebos.

Howick writes “[normally] we have to believe
they are “real” treatments, which means the
doctor would have to lie to us and say that the
placebo was actually a real treatment. Or, in the
case of a clinical trial, that it might be a real
treatment. After all, if a doctor handed you a pill
and said, ‘this is just a sugar pill’, you’d probably
assume it wouldn’t work. But sometimes our
assumptions are mistaken” (2017). Previously,
the belief was that the placebo effect only
worked when patients believed they were
taking real medicine. With this study, this is no
longer necessarily the case.
According to Howick, “the history of openlabel placebos can be traced back to at least
1965 when Baltimore doctors, Lee Park and Uno
Covi, gave open placebos to 15 neurotic patients.
They told the patients: ‘Many people with your
kind of condition have been helped by what are
sometimes called sugar pills and we feel that a
so-called sugar pill may help you too’” (2017).
Many of the patients got better. Paradoxically,
since these were neurotic patients, they thought
that the doctors had lied to them and given
them real drugs.
The first study reviewed was led by
Professor Ted Kaptchuk, of Harvard Medical
School, who gave 80 IBS patients, including
Buonanno (Fleming, 2017), either no treatment
or open-label placebo pills (Charlesworth,
2017). He found those who took placebos for
three weeks experienced greater improvements
in symptoms, including less severe pain. In
another of the studies in Howick’s review,

“Previously, the
belief was that
the placebo effect
only worked when
patients believed
they were taking
real medicine. With
this study, this is no
longer necessarily
the case.”

Figure 3: Pavlov’s dogs and
their keepers. Ivan Pavlov
demonstrated classical
conditioning by training dogs
to salivate by association.
Source: Wikimedia Commons
(Credit: Wellcome Images)
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“Fortunately, the
review of openlabel placebos
demonstrates
something more
general: placebo
effects are real
for many common
conditions and
people can use
the placebo effect
without placebo
pills.”
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chronic lower back pain patients openly given
dummy pills to add to their existing treatments
reported an average 30% pain reduction. In
the three other review studies, people given
open-label pills reported reduced symptoms
for depression, lower back pain, and attention
deficit hyperactivity disorder.
“Open-label placebos probably work in two
ways,” writes Howick. “The first is expectation.
Open-label are usually given with a positive
suggestion: the doctor will tell the patient the
pill is just a placebo but adds that it ‘produces
significant improvement for patients like you’.
This positive suggestion creates a positive
expectation, which can activate the reward
mechanisms in the brain and help the body
produce its own pain-reducing substances, such
as endorphins” (2017).
The second possible explanation is
conditioning. Pavlov was a Russian physiologist
who accidently discovered the phenomenon
of classical conditioning while studying dogs’
gastric systems (Specter, 2014). He found that
dogs would salivate when they heard or smelled
food in anticipation of feeding. This is an expected
response given the role of saliva in digestion.
However, the dogs also began to salivate when
events occurred which would otherwise be
unrelated to feeding. By playing sounds to the
dogs prior to feeding them, Pavlov showed that
they could be conditioned to associate neutral,
unrelated events with being fed. Just as Pavlov’s
dogs learned to associate the sound of a bell
with food and began salivating whenever they
heard the bell, most of us have been conditioned
to expect a positive outcome when a trusted
doctor gives a treatment. “So even though we
know a pill is a placebo,” Howick writes, “our
bodies may react in a way that helps us heal.
There have been several studies, including one
in humans, showing that the immune system
can be activated much in the same way that
Pavlov’s dogs salivated at the mere sound of a
bell” (2017).
Since open-label placebos have been shown
to improve symptoms, should they be made
available? After all, they seem to help people
with nowhere else to go, like Buonanno, and
have no side effects being made from sugar
or other harmless substances. According to
Howick, no (2017). “That may be unwise because
it would support a pill-popping, overmedicalized
culture.” Fortunately, the review of open-label
placebos demonstrates something more general:
placebo effects are real for many common
conditions and people can use the placebo effect
without placebo pills. Doctors who give positive
messages and take time to communicate with
enhanced empathy to patients can bring about
positive benefits with or without pills. “Far from
being unethical,” Howick says, “since placebo

effects can benefit many patients it is probably
unethical not to exploit them.”
The placebo effect, though already poorly
understood and mysterious, seems to be
evolving in strength and breadth right before
our very eyes. A few months ago, most were
confident that placebo effects only occurred
when patients were unaware they were taking
a placebo. And yet recently we learned that
wasn’t the case. The consequences of the
placebo effect’s “new abilities” are far-reaching
and represent a double-edged sword. On the one
hand, people who find no succor from presently
available pharmaceuticals may now find relief.
On the other hand, many people who need new,
upcoming treatments may have their hopes
dashed by a sudden discontinuity of research
into a treatment. Just as our understanding
of the placebo effect seems to be evolving,
so is its future role in medicine. Will we find
it to be an enemy, stealing hope away from
anxious patients? Or will we find in it a novel
and previously-untapped base for treatment,
helping doctors assist suffering patients without
harsh side-effects? D
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